{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:54:57Z","timestamp":1792144497095,"version":"4.4.0"},"reference-count":94,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Drug-induced thrombotic microangiopathy (DITMA) represents 10%\u201313% of all thrombotic microangiopathy (TMA) cases and about 20%\u201330% of secondary TMAs, just behind pregnancy-related and infection-related forms. Although the list of drugs potentially involved as causative for TMA are rapidly increasing, the scientific literature on DITMA is quite scarce (mostly as individual case reports or little case series), leading to poor knowledge of pathophysiological mechanisms and clinical management. In this review, we focused on these critical aspects regarding DITMA. We provided an updated list of TMA-associated drugs that we selected from a scientific literature review, including only those drugs with a definite or probable causal association with TMA. The list of drugs is heterogeneous and could help physicians from several different areas to be familiar with DITMA. We describe the clinical features of DITMA, presenting the full spectrum of clinical manifestations, from systemic to kidney-limited forms. We also analyze the association between signs\/symptoms (i.e., malignant hypertension, thrombocytopenia) and specific DITMA causative drugs (i.e., interferon, ticlopidine). We highlighted their multiple different pathophysiological mechanisms, being frequently classified as immune-mediated (idiosyncratic) and dose-related\/toxic. In particular, to clarify the role of the complement system and genetic deregulation of the related genes, we conducted a revision of the scientific literature searching for DITMA cases who underwent renal biopsy and\/or genetic analysis for complement genes. We identified a complement deposition in renal biopsies in half of the patients (37\/66; 57%), with some drugs associated with major deposits (i.e., gemcitabine and ramucirumab), particularly in capillary vessels (24\/27; 88%), and other with absent deposits (tyrosine kinase inhibitors and intraocular anti-VEGF). We also found out that, differently from other secondary TMAs (such as pregnancy-related-TMA and malignant hypertension TMA), complement genetic pathological mutations are rarely involved in DITMA (2\/122, 1.6%). These data suggest a variable non-genetic complement hyperactivation in DITMA, which probably depends on the causative drug involved. Finally, based on recent literature data, we proposed a treatment approach for DITMA, highlighting the importance of drug withdrawal and the role of therapeutic plasma-exchange (TPE), rituximab, and anti-complementary therapy.<\/jats:p>","DOI":"10.3389\/fphar.2022.1088031","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T07:55:42Z","timestamp":1673250942000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":83,"title":["Drug-induced thrombotic microangiopathy: An updated review of causative drugs, pathophysiology, and management"],"prefix":"10.3389","volume":"13","author":[{"given":"Tommaso","family":"Mazzierli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Allegretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Maffini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Allinovi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"E30","DOI":"10.3978\/j.issn.2078-6891.2013.042","article-title":"Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review","volume":"5","author":"Al Ustwani","year":"2014","journal-title":"J. Gastrointest. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2014.00052","article-title":"Atypical hemolytic uremic syndrome post-kidney transplantation: Two case reports and review of the literature","volume":"1","author":"Alasfar","year":"2014","journal-title":"Front. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/brainsci11101341","article-title":"Safety and efficacy of eculizumab therapy in multiple sclerosis: A case series","volume":"11","author":"Allinovi","year":"2021","journal-title":"Brain Sci."},{"key":"B5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/ckj\/sfw143","article-title":"Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab","volume":"10","author":"Allinovi","year":"2017","journal-title":"Clin. Kidney J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"7063145","DOI":"10.1155\/2018\/7063145","article-title":"Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib","volume":"2018","author":"Atallah-Yunes","year":"2018","journal-title":"Case Rep. Hematol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2141.2007.06588.x","article-title":"Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab","volume":"137","author":"Au","year":"2007","journal-title":"Br. J. Haematol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"566678","DOI":"10.3389\/fmed.2021.566678\/full","article-title":"Retrospective and systematic analysis of causes and outcomes of thrombotic microangiopathies in routine clinical practice: an 11-year study","volume":"8","author":"Beloncle","year":"2021","journal-title":"Front. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.12303","article-title":"Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the southern network on adverse reactions (SONAR)","volume":"161","author":"Bennett","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jacc.2007.04.093","article-title":"Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP research group and the RADAR project","volume":"50","author":"Bennett","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1185\/030079908x261005","article-title":"Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells","volume":"24","author":"Bezwada","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","article-title":"Case report: Carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with eculizumab","volume":"20","author":"Bhutani","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leukemia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/ckj\/sfaa195","article-title":"Thrombotic microangiopathies assessment: mind the complement","volume":"14","author":"Blasco","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B15","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/cjn.00620117","article-title":"Thrombotic microangiopathy and the kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/cjn.00280117","article-title":"Hemolytic uremic syndrome in pregnancy and postpartum","volume":"12","author":"Bruel","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.kint.2019.07.006","article-title":"Complement inhibitors are useful in secondary hemolytic uremic syndromes","volume":"96","author":"Caravaca-Fontan","year":"2019","journal-title":"Kidney Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"key":"B20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/rhu.0000000000000684","article-title":"Development of thrombotic thrombocytopenic purpura in association with the monoclonal antibody, golimumab, used to treat rheumatoid arthritis, in a case with literature review","volume":"24","author":"Cepeda","year":"2018","journal-title":"JCR J. Clin. Rheumatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fmed.2020.00212","article-title":"An update in drug-induced thrombotic microangiopathy","volume":"7","author":"Chatzikonstantinou","year":"2020","journal-title":"Front. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1093\/ckj\/sfab114","article-title":"Renal diseases secondary to interferon-\u03b2 treatment: a multicentre clinico-pathological study and systematic literature review","volume":"14","author":"Dauvergne","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"6004","DOI":"10.1038\/s41598-017-05173-8","article-title":"A haplotype in CFH family genes confers high risk of rare glomerular nephropathies","volume":"7","author":"Ding","year":"2017","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1042\/BCJ20170272","article-title":"Protease-activated receptor-2 promotes kidney tubular epithelial inflammation by inhibiting autophagy via the PI3K\/Akt\/mTOR signalling pathway","volume":"474","author":"Du","year":"2017","journal-title":"Biochem. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.kint.2019.08.001","article-title":"Complement inhibitors are not useful in secondary hemolytic uremic syndromes","volume":"96","author":"Duineveld","year":"2019","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/nejmoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","article-title":"Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics","volume":"17","author":"Fakhouri","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1681\/asn.2009070706","article-title":"Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations","volume":"21","author":"Fakhouri","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.imbio.2016.10.014","article-title":"Complement activation, inflammation and relative ADAMTS13 deficiency in secondary thrombotic microangiopathies","volume":"222","author":"Farkas","year":"2017","journal-title":"Immunobiology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2215\/cjn.05830518","article-title":"Complement gene variants and shiga toxin\u2013producing Escherichia coli\u2013associated hemolytic uremic syndrome","volume":"14","author":"Fr\u00e9meaux-Bacchi","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1681\/asn.2016090995","article-title":"Maternal and fetal outcomes of pregnancies in women with atypical hemolytic uremic syndrome","volume":"29","author":"Gaggl","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.6004\/jnccn.2017.0108","article-title":"Thrombotic thrombocytopenic purpura associated with pegylated interferon alfa-2a use in a patient with polycythemia vera","volume":"15","author":"Gangaraju","year":"2017","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B38","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1056\/NEJMcps1606750","article-title":"After the Party\u2019s over","volume":"376","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"886","DOI":"10.7326\/0003-4819-129-11_part_1-199812010-00009","article-title":"Drug-induced thrombocytopenia: a systematic review of published case reports","volume":"129","author":"George","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.mehy.2013.05.030","article-title":"Does dysregulated complement activation contribute to haemolytic uraemic syndrome secondary to Streptococcus pneumoniae?","volume":"81","author":"Gilbert","year":"2013","journal-title":"Med. Hypotheses"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1053\/j.ajkd.2010.06.006","article-title":"The role of endothelial cell injury in thrombotic microangiopathy","volume":"56","author":"Goldberg","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201ckidney disease: Improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int."},{"key":"B44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jca.20213","article-title":"Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?","volume":"24","author":"Gore","year":"2009","journal-title":"J. Clin. Apher."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00280-010-1258-4","article-title":"Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura\/hemolytic uremic syndrome (TTP\/HUS) with rituximab","volume":"65","author":"Gourley","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12882-021-02470-3","article-title":"Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre","volume":"22","author":"Grall","year":"2021","journal-title":"BMC Nephrol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiological Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1681\/ASN.2004100843","article-title":"Renal failure associated with cancer and its treatment: an update","volume":"16","author":"Humphreys","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/md.0000000000000207","article-title":"Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center","volume":"93","author":"Izzedine","year":"2014","journal-title":"Medicine"},{"key":"B51","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2015.02.340","article-title":"Thrombotic microangiopathy, cancer, and cancer drugs","volume":"66","author":"Izzedine","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1055\/s-0032-1328894","article-title":"Ticlopidine-clopidogrel-and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the southern network on adverse reactions (SONAR)","volume":"38","author":"Jacob","year":"2012","journal-title":"Semin. Thromb. Hemost."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e28908","DOI":"10.1097\/md.0000000000028908","article-title":"Successful treatment of thrombotic thrombocytopenic purpura with plasmapheresis and anti-CD20 antibodies in a patient with immune thrombocytopenia and systemic lupus erythematosus: Case report","volume":"101","author":"Jung","year":"2022","journal-title":"Medicine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s00277-017-3063-1","article-title":"Clinical dissection of thrombotic microangiopathy","volume":"96","author":"Kang","year":"2017","journal-title":"Ann. Hematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2016-05-715987","article-title":"Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature","volume":"128","author":"Kavanagh","year":"2016","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12882-017-0512-y","article-title":"Case report - atypical hemolytic uremic syndrome triggered by influenza B","volume":"18","author":"Kobbe","year":"2017","journal-title":"BMC Nephrol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.critrevonc.2017.02.011","article-title":"Interferon induced thrombotic microangiopathy (TMA): Analysis and concise review","volume":"112","author":"Kundra","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13730-020-00454-0","article-title":"Thrombotic thrombocytopenic purpura associated to dual checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Lafranchi","year":"2020","journal-title":"Cen. case Rep."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1080\/15548627.2015.1049799","article-title":"Endothelial cell and podocyte autophagy synergistically protect from diabetes-induced glomerulosclerosis","volume":"11","author":"Lenoir","year":"2015","journal-title":"Autophagy"},{"key":"B62","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin. Kidney J."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.2215\/cjn.06230614","article-title":"Molecules great and small: The complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jash.2015.12.007","article-title":"The endothelium as the common denominator in malignant hypertension and thrombotic microangiopathy","volume":"10","author":"Mathew","year":"2016","journal-title":"J. Am. Soc. Hypertens."},{"key":"B65","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000435807","article-title":"Improvement in gemcitabine-induced thrombotic microangiopathy with rituximab in a patient with ovarian cancer: Mechanistic considerations","volume":"5","author":"Murugapandian","year":"2015","journal-title":"Case Rep. Nephrol. Dial."},{"key":"B66","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.molimm.2015.03.246","article-title":"Atypical aHUS: State of the art","volume":"67","author":"Nester","year":"2015","journal-title":"Mol. Immunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/b978-0-323-44942-7.00160-6","article-title":"The role of plasmapheresis in critical illness","author":"Nguyen","year":"2019","journal-title":"Crit. Care Nephrol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1053\/j.ajkd.2015.03.040","article-title":"Glomerular diseases dependent on complement activation, including atypical hemolytic uremic syndrome, membranoproliferative glomerulonephritis, and C3 glomerulopathy: Core curriculum 2015","volume":"66","author":"Noris","year":"2015","journal-title":"Am. J. Kidney Dis."},{"key":"B70","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11255-013-0401-7","article-title":"Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis","volume":"46","author":"Orvain","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice \u2013 evidence\u2010based approach from the writing committee of the American society for apheresis: The eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"B72","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1053\/j.ajkd.2017.05.023","article-title":"Quinine-induced thrombotic microangiopathy: A report of 19 patients","volume":"70","author":"Page","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.2215\/cjn.05830519","article-title":"Complement activation and thrombotic microangiopathies","volume":"14","author":"Palomo","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"27915","DOI":"10.1038\/srep27915","article-title":"Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling","volume":"6","author":"Rodrigues-Diez","year":"2016","journal-title":"Sci. Rep."},{"key":"B78","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.1182\/blood-2018-99-117723","article-title":"Clinical associations, treatment, and outcomes of renal-limited thrombotic microangiopathy","volume":"132","author":"Saba","year":"2018","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"E241","DOI":"10.1002\/ajh.25208","article-title":"Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ckj\/sfaa101","article-title":"Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy","volume":"14","author":"Salhi","year":"2021","journal-title":"Clin. Kidney J."},{"key":"B81","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: The seventh special issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J. Clin. Apher."},{"key":"B82","doi-asserted-by":"publisher","first-page":"503252","DOI":"10.1016\/j.mrgentox.2020.503252","article-title":"Mitomycin C induced genotoxic stress in endothelial cells is associated with differential expression of proinflammatory cytokines","author":"Sinitsky","year":"2020","journal-title":"Mutat. Research\/Genetic Toxicol. Environ. Mutagen."},{"key":"B83","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2337\/db15-0473","article-title":"Impaired podocyte autophagy exacerbates proteinuria in diabetic nephropathy","volume":"65","author":"Tagawa","year":"2016","journal-title":"Diabetes"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.ekir.2022.05.002","article-title":"Interferon-\u03b21a-Induced thrombotic microangiopathy: Possible implication of the alternative pathway of the complement","volume":"7","author":"Taghavi","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"B85","doi-asserted-by":"publisher","first-page":"794","DOI":"10.7326\/0003-4819-132-10-200005160-00005","article-title":"Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura","volume":"132","author":"Tsai","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic microangiopathy in oncology - a review","volume":"14","author":"Val\u00e9rio","year":"2021","journal-title":"Transl. Oncol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"E16","DOI":"10.1053\/ajkd.2002.35758","article-title":"Gemcitabine-associated hemolytic-uremic syndrome","volume":"40","author":"Walter","year":"2002","journal-title":"Am. J. Kidney Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/asheducation-2017.1.632","article-title":"Plasma exchange in thrombotic microangiopathies (TMAs) other than thrombotic thrombocytopenic purpura (TTP)","volume":"2017","author":"Winters","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B89","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1038\/ki.2008.613","article-title":"Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008)","volume":"75","author":"Zakarija","year":"2009","journal-title":"Kidney Int. Suppl."},{"key":"B90","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/imj.12055","article-title":"Thrombotic thrombocytopenic purpura associated with adalimumab (Humira) treatment in Crohn disease","volume":"43","author":"Zbaras","year":"2013","journal-title":"Intern. Med. J."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ndt\/gfaa280","article-title":"Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis","volume":"36","author":"Zhang","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"key":"B92","doi-asserted-by":"publisher","first-page":"405","DOI":"10.14670\/HH-18-178","article-title":"p66Shc regulates podocyte autophagy in high glucose environment through the Notch-PTEN-PI3K\/Akt\/mTOR pathway","volume":"35","author":"Zheng","year":"2020","journal-title":"Histol. Histopathol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1182\/blood.2019001040","article-title":"Synergistic effects of ADAMTS13 deficiency and complement activation in pathogenesis of thrombotic microangiopathy","volume":"134","author":"Zheng","year":"2019","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","article-title":"Gemcitabine-associated thrombotic thrombocytopenic purpura","volume":"8","author":"Zupancic","year":"2007","journal-title":"Lancet Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1088031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T07:55:49Z","timestamp":1673250949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1088031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":94,"alternative-id":["10.3389\/fphar.2022.1088031"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1088031","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1088031"}}